RXRX’s Stock Market Pendulum: Swinging Between Gains and Losses

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The metric has seen a significant loss of -18.79% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -22.57%. Over the past 30 days, the price of RXRX has fallen by 31.03%. And in the last five days, it has surged by 31.34%.

The market performance of Recursion Pharmaceuticals Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $12.36 on 02/18/25, with the lowest value for the same timeframe being $3.79, recorded on 04/09/25.

52-week price history of RXRX Stock

The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Recursion Pharmaceuticals Inc’s current trading price is -55.58% away from its 52-week high, while its distance from the 52-week low is 44.85%. The stock’s price range for this period has been between $3.79 and $12.36. The Healthcare sector company’s shares saw a trading volume of about 59.74 million for the day, which was higher than the average daily volume of 20.85 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Recursion Pharmaceuticals Inc (RXRX) has experienced a quarterly decline of -16.69% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.23B.

How Moving Averages and Trading Volume Data Work Together

RXRX’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for RXRX stands at 0.10. Similarly, the long-term debt-to-equity ratio is also 0.08.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.